Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.0937
-0.0089 (-8.67%)
At close: Nov 6, 2026, 4:00 PM EST
0.0955
+0.0018 (1.92%)
After-hours: Nov 6, 2026, 7:39 PM EST
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $5.15M in the quarter ending June 30, 2026, with 34.90% growth. This brings the company's total for the last twelve months to $20.90M, up 45.21% year-over-year. In the year 2025, Vivos Therapeutics had annual revenue of $17.44M with 16.05% growth. That makes Vivos Therapeutics the 33,591st largest company in the world by revenue and 4,404th in the United States.
Revenue (ttm)
$20.90M
Revenue Growth
+45.21%
P/S Ratio
0.09
Revenue / Employee
$77,415
Employees
270
Market Cap
1.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.44M | 2.41M | 16.05% |
| Dec 31, 2024 | 15.03M | 1.23M | 8.91% |
| Dec 31, 2023 | 13.80M | -2.22M | -13.87% |
| Dec 31, 2022 | 16.02M | -861.00K | -5.10% |
| Dec 31, 2021 | 16.89M | 3.82M | 29.23% |
| Dec 31, 2020 | 13.07M | 1.67M | 14.68% |
| Dec 31, 2019 | 11.39M | 7.60M | 200.43% |
| Dec 31, 2018 | 3.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baird Medical Investment Holdings | 24.49M |
| WORK Medical Technology Group LTD | 10.72M |
| Nuwellis | 9.01M |
| Beyond Air | 7.69M |
| INVO Fertility | 7.53M |
| VolitionRx | 2.46M |
| 20/20 Biolabs | 2.04M |
| Co-Diagnostics | 721.39K |
VVOS News
- 6 days ago - Vivos Therapeutics Proxy statement: Proxy filing - Filings
- 10 days ago - Vivos Therapeutics Proxy statement: Proxy filing - Filings
- 18 days ago - Vivos Therapeutics regains Nasdaq stockholders’ equity compliance - TheFly
- 18 days ago - Vivos Therapeutics Proxy statement: Proxy filing - Filings
- 18 days ago - Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard - GlobeNewsWire
- 20 days ago - Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel - GlobeNewsWire
- 20 days ago - Vivos Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Vivos Therapeutics to acquire 11% stake in SOD Sciences for $12M in preferred - TheFly